Keywords
Last Name
Institution

Kathryn J Eagye MPH

TitleSenior Scientist
InstitutionHartford Hospital
DepartmentResearch
Address80 Seymour Street
Phone860-545-6127
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med. 2012 Apr; 40(4):1329-32. PMID: 22425824.
      View in: PubMed
    2. Eagye KJ, Nicolau DP. Selection of prophylactic antimicrobial agent may affect incidence of infection in small bowel and colorectal surgery. Surg Infect (Larchmt). 2011 Dec; 12(6):451-7. PMID: 22142316.
      View in: PubMed
    3. Eagye KJ, Nicolau DP. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. J Antimicrob Chemother. 2011 Jun; 66(6):1392-5. PMID: 21459897.
      View in: PubMed
    4. Eagye KJ, Nicolau DP. Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals. Adv Ther. 2011 Apr; 28(4):326-33. PMID: 21445549.
      View in: PubMed
    5. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy. 2010 May; 30(5):453-62. PMID: 20411997.
      View in: PubMed
    6. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol. 2010 May; 31(5):485-90. PMID: 20334550.
      View in: PubMed
    7. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals. Clin Ther. 2009 Nov; 31(11):2678-88. PMID: 20110010.
      View in: PubMed
    8. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt). 2009 Aug; 10(4):323-31. PMID: 19622027.
      View in: PubMed
    9. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2009 Aug; 30(8):746-52. PMID: 19583513.
      View in: PubMed
    10. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care. 2010 Mar; 25(1):69-77. PMID: 19427167.
      View in: PubMed
    11. Eagye KJ, Nicolau DP. Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs. Am J Surg. 2009 Sep; 198(3):359-67. PMID: 19306972.
      View in: PubMed
    12. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med. 2009 Feb; 30(1):116-23. PMID: 19199193.
      View in: PubMed
    13. Eagye KJ, Nicolau DP, Lockhart SR, Quinn JP, Doern GV, Gallagher G, Abramson MA. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004. Ann Clin Microbiol Antimicrob. 2007; 6:11. PMID: 17908321; PMCID: PMC2134929.
    14. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther. 2007 May; 29(5):889-99. PMID: 17697907.
      View in: PubMed
    15. Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect (Larchmt). 2007 Apr; 8(2):215-26. PMID: 17437367.
      View in: PubMed
    16. Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy. Clin Microbiol Infect. 2007 Jun; 13(6):579-85. PMID: 17331121.
      View in: PubMed
    17. Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents. 2006 Oct; 28(4):340-4. PMID: 16930951.
      View in: PubMed
    Eagye's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _